Nexus Surgical (538874)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me be blunt: I would not put ₹1 of my own money into Nexus Surgical at ₹20.24 without understanding the business, and the available data do not let me understand it. The market cap is only ₹11 crore, so any serious investor would find it too small. The numbers are flashy: ROE 67.88%, ROCE 83.95%, sales growth 97.97%, profit growth 54.55%, P/E 17.57, PEG 0.23. But Graham warned me to look behind the ratio. Book value is just ₹1.62 per share, so the stock trades at 12.49 times book. A high return on a tiny equity base is not the same as a wonderful business. The latest quarter tells a different story: sales are only ₹3 crore and net profit is effectively ₹0 crore. That is a microscopic earnings base, and the growth may be a rounding error. There is no dividend. Promoter holding is listed as N/A, which is unacceptable for a microcap. Debt/equity is N/A too. The company is classified as Other Financial Services despite the surgical name, so I cannot even confidently say what it does. The Piotroski score of 7 is a small positive, but it cannot rescue a stock selling at 12.5 times book with a blank information profile. This is a fast grower on a spreadsheet, not a business I can evaluate with margin of safety. I will pass.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer